Biogen (BIIB)
(Delayed Data from NSDQ)
$172.03 USD
-1.01 (-0.58%)
Updated Nov 11, 2024 04:00 PM ET
After-Market: $172.03 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
A Value C Growth D Momentum B VGM
Price, Consensus and EPS Surprise
BIIB 172.03 -1.01(-0.58%)
Will BIIB be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for BIIB based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for BIIB
Eli Lilly Falls More Than 10% in a Month: Buy, Sell or Hold the Stock?
Immunovant's Q2 Loss Wider Than Expected, Pipeline in Focus
BIIB: What are Zacks experts saying now?
Zacks Private Portfolio Services
Allogene's Q3 Loss Narrower Than Expected, Sales Nil
IOVA Posts Narrower-Than-Expected Q3 Loss, Amtagvi Sales Drive Top line
Denali Q3 Earnings Miss Estimates, Pipeline Progress Encouraging
Other News for BIIB
QQQ ETF Update, 11/11/2024
Needham biotech analysts hold an analyst/industry conference call
Needham biotech analysts hold an analyst/industry conference call
VOO ETF Update, 11/8/2024???
December 27th Options Now Available For Biogen (BIIB)